PTGS2 and colorectal cancer: New indications introduced by drug repositioning include thalidomide, a sedative hypnotic agent, for multiple myeloma and leprosy [2–4]; a COX-2 inhibitor for pancreatic cancer and colorectal cancer [13, 14]; aspirin, an NSAID, for colorectal cancer [5]; and metformin, an antidiabetic drug, for endometrial cancer [6].